PubMed HealthSearch

PubMed · 7796548

Headache.

Abstract

An attempt has been made to provide an overview of headache management for the primary healthcare provider for women. No attempt has been made to delineate for the clinician all care related to the difficult-to-manage headache patient, but at the same time, information has been provided that should assist the clinician in treating this common disorder. Often, a comprehensive approach is needed, and appropriate referral may be necessary to other healthcare providers who are capable of providing more specific services. The women's healthcare provider often has important psychologic and environmental information necessary to provide meaningful early intervention. This common complaint in patients is often overlooked and/or dismissed as "happening to everybody," thus patients are unnecessarily neglected. Not only can specific therapy be provided for the headache patient, but this complaint can serve to alert caregivers to other organic and emotional problems.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Laube. 1995. Headache.. https://doi.org/10.1097/00003081-199503000-00022

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.

BACKGROUND: Disturbed fibrinolytic function may influence the progression of coronary atherosclerosis and contribute to thrombotic cardiovascular (CV) events. METHODS AND RESULTS: In the Angina Prognosis Study in Stockholm (APSIS), patients with stable angina pectoris were studied prospectively during double-blind treatment with metoprolol or verapamil. Various measures of fibrinolytic function were studied in 631 (of 809) patients. During a median follow-up time of 3.2 years (2132 patient-years), 32 patients suffered a CV death, 21 had a nonfatal myocardial infarction (MI), and 77 underwent revascularization. Plasma levels of tissue plasminogen activator (TPA) activity and antigen (ag), plasminogen activator inhibitor (PAI-1) activity at test, and TPA responses to exercise were determined at baseline and after 1 month's treatment and were related to subsequent fatal and nonfatal CV events. Univariate Cox regression analysis revealed that elevated levels of TPA-ag at rest (P < .05), high PAI-1 activity (P < .05), and low TPA-ag responses to exercise (P < .05) were associated with increased risk of subsequent CV death. After adjustment for baseline risk factors, TPA-ag independently predicted CV death or MI. In addition, PAI-1 activity independently predicted CV death or MI in male patients. Verapamil treatment was associated with a 10% decrease of TPA-ag levels and metoprolol treatment with a 2% increase (P < .001 for treatment difference). CONCLUSIONS: Plasma TPA-ag levels at rest, and among male patients PAI-1 activity as well, independently predict subsequent CV death or MI in patients with stable angina pectoris.

Adrenergic beta-Antagonists